Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Provided By GlobeNewswire

Last update: Nov 14, 2024

Overwhelming shareholder support in favour of take-private transaction with Aditxt

Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year